FDA gives the green light to AstraZeneca's rare blood disorder drug Voydeya, following approval in Japan
AstraZeneca’s Voydeya, an add-on treatment for a rare disorder in which red blood cells break up too early, scored approval in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
